Ixazomib Plus Pomalidomide, Dexamethasone in Relapsed/Refractory Myeloma

Amrita Y. Krishnan, MD, shares the promising preliminary results from a phase I/II study of the triplet regimen ixazomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

SHARE